Mobile website
Clinical Research
Up-regulation of calreticulin expression improves the efficacy of rituximab combined CHOP treatment for B-cell non-Hodgkin’s lymphoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective : To evaluate the clinical efficacy of rituximab (R) combined CHOP ( R-CHOP) treatment on B-cell non-Hodgkin＇s lymphoma (NHL) and its influence on the expression of calreticulin (CRT). Methods: Totally 48 patients (From Jul. 2008 to Feb. 2011 in Affiliated Hospital of Nantong University) with previously untreated B-cell lymphoma were divided into R-CHOP group (25 cases) and CHOP group (23 cases). R-CHOP group was treated with R-CHOP chemotherapy and CHOP group was treated with CHOP chemotherapy. After 6 treatment courses, the clinical efficacy, adverse effect and the expression of CRT on CD20+ B cells were compared between these two groups. Results: The complete remission rate was 80.0% and the total effective rate was 92.0% in the R-CHOP group. The complete remission rate was 56.5% and the total effective rate was 696% in the CHOP group. There was a significant difference in the complete remission rate and the total effective rate between the two groups (P<0.05). There was no significant difference in adverse events between the two groups (P>005). The expression of CRT on CD20+ B cells in the R-CHOP group was higher than the CHOP group (\[255.00±5.57\] vs \[216.00±3.61\], P<0.05). Conclusion: Rituximab can improve the clinical effciency of CHOP in the treatment of B-cell NHL, which may be related with the expression of CRT induced by combined treatment.
Keywords:
Project Supported:
Clc Number:
